GYL Financial Synergies LLC purchased a new position in Danaher Co. (NYSE:DHR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,627 shares of the conglomerate’s stock, valued at approximately $271,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of DHR. Advisor Partners LLC increased its stake in Danaher by 17.3% during the fourth quarter. Advisor Partners LLC now owns 19,477 shares of the conglomerate’s stock worth $2,008,000 after acquiring an additional 2,868 shares during the last quarter. Stokes Capital Advisors LLC increased its stake in Danaher by 15.0% during the fourth quarter. Stokes Capital Advisors LLC now owns 21,215 shares of the conglomerate’s stock worth $2,188,000 after acquiring an additional 2,775 shares during the last quarter. BKD Wealth Advisors LLC acquired a new stake in Danaher during the fourth quarter worth $253,000. Xact Kapitalforvaltning AB increased its stake in Danaher by 0.9% during the fourth quarter. Xact Kapitalforvaltning AB now owns 107,127 shares of the conglomerate’s stock worth $11,047,000 after acquiring an additional 908 shares during the last quarter. Finally, Securian Asset Management Inc increased its stake in Danaher by 1.8% during the fourth quarter. Securian Asset Management Inc now owns 63,391 shares of the conglomerate’s stock worth $6,537,000 after acquiring an additional 1,128 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.
Several equities research analysts have issued reports on DHR shares. Royal Bank of Canada reissued a “hold” rating and set a $102.00 target price on shares of Danaher in a research note on Wednesday, December 19th. Janney Montgomery Scott raised Danaher from a “neutral” rating to a “buy” rating in a research note on Monday, February 25th. Needham & Company LLC started coverage on Danaher in a research note on Wednesday, January 2nd. They set a “buy” rating and a $114.00 target price for the company. JPMorgan Chase & Co. reissued an “overweight” rating and set a $140.00 target price on shares of Danaher in a research note on Monday, March 4th. Finally, Cowen reissued a “buy” rating and set a $110.00 target price on shares of Danaher in a research note on Monday, January 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $123.31.
Shares of NYSE DHR opened at $128.07 on Tuesday. Danaher Co. has a twelve month low of $94.59 and a twelve month high of $129.42. The company has a quick ratio of 1.07, a current ratio of 1.47 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $90.32 billion, a PE ratio of 28.33, a PEG ratio of 2.37 and a beta of 1.04.
Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 29th. The conglomerate reported $1.28 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.01. Danaher had a return on equity of 11.64% and a net margin of 13.33%. The business had revenue of $5.40 billion during the quarter, compared to analysts’ expectations of $5.33 billion. During the same period in the previous year, the firm posted $1.19 earnings per share. The company’s revenue was up 6.2% on a year-over-year basis. As a group, research analysts anticipate that Danaher Co. will post 4.76 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.53%. This is an increase from Danaher’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend is Thursday, March 28th. Danaher’s payout ratio is 14.16%.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Read More: NASDAQ Stock Market Explained
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.